In the present study, we collected retrospective data on TP53-mutated patients from centers affiliated with the French Innovative Leukemia Organization-CLL (FILO) in GBMHM (French Molecular Biology Group in Hematology) laboratories. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.